Outcome of patients with chronic active EBV disease
| Patient . | Race/sex . | Age at onset, y . | Age at death, y . | Outcome . |
|---|---|---|---|---|
| Unknown whether B-, T-, or NK-cell disease | ||||
| 1 | WM | 28 | 38 | Died, LPD, MDS/acute myelomonocytic leukemia |
| 2 | WM | 13 | 30 | Died, infection |
| 4 | AF | 11 | 14 | Died, LPD, pneumonia |
| 5 | WM | 22 | 23 | Died, LPD, pulmonary thrombosis |
| B-cell disease | ||||
| 3 | WM | 9 | 17 | Died, progressive disease, disseminated candidiasis |
| 6 | WM | 18 | 24 | Died, progressive disease, Aspergillus pneumonia, brain abscess |
| 7 | BF | 13 | 17 | Died, B-cell lymphoma |
| 8 | WM | 29 | 36 | Died, cirrhosis (alcohol-related) |
| 9 | WM | 17 | Alive (37 y) | Alive 11 years after BMT, EBV negative |
| 11 | WF | 20 | 31 | Died, progressive disease |
| 12 | WM | 51 | Alive (64 y) | Alive 6 years after HSCT, EBV positive, mild GVHD, infections |
| 13 | WM | 44 | 45 | Died, central pontine myelinolysis after HSCT, residual B-cell lymphoma |
| 14 | AF | 22 | Alive (30 y) | Alive with B-cell LPD, 1 year after autologous EBV CTLs (LCL-specific and LMP1/2- specific cells) |
| 16 | WM | 29 | 31 | Died, residual B-cell lymphoma after HSCT × 3 |
| 17 | HF | 5 | Alive (16 y) | Alive 6 years after HSCT, EBV negative |
| T-cell disease | ||||
| 10 | WF | 9 | 15 | Died, T-cell lymphoma |
| 15 | HM | 8 | Alive (15 y) | Alive 2 years after HSCT |
| 18 | AM | 4 | 9 | Died, 4 years after HSCT, T-cell lymphoma |
| NK-cell disease | ||||
| 19 | HM | 7 | Alive (14 y) | Alive 2 years after HSCT in complete remission |
| Patient . | Race/sex . | Age at onset, y . | Age at death, y . | Outcome . |
|---|---|---|---|---|
| Unknown whether B-, T-, or NK-cell disease | ||||
| 1 | WM | 28 | 38 | Died, LPD, MDS/acute myelomonocytic leukemia |
| 2 | WM | 13 | 30 | Died, infection |
| 4 | AF | 11 | 14 | Died, LPD, pneumonia |
| 5 | WM | 22 | 23 | Died, LPD, pulmonary thrombosis |
| B-cell disease | ||||
| 3 | WM | 9 | 17 | Died, progressive disease, disseminated candidiasis |
| 6 | WM | 18 | 24 | Died, progressive disease, Aspergillus pneumonia, brain abscess |
| 7 | BF | 13 | 17 | Died, B-cell lymphoma |
| 8 | WM | 29 | 36 | Died, cirrhosis (alcohol-related) |
| 9 | WM | 17 | Alive (37 y) | Alive 11 years after BMT, EBV negative |
| 11 | WF | 20 | 31 | Died, progressive disease |
| 12 | WM | 51 | Alive (64 y) | Alive 6 years after HSCT, EBV positive, mild GVHD, infections |
| 13 | WM | 44 | 45 | Died, central pontine myelinolysis after HSCT, residual B-cell lymphoma |
| 14 | AF | 22 | Alive (30 y) | Alive with B-cell LPD, 1 year after autologous EBV CTLs (LCL-specific and LMP1/2- specific cells) |
| 16 | WM | 29 | 31 | Died, residual B-cell lymphoma after HSCT × 3 |
| 17 | HF | 5 | Alive (16 y) | Alive 6 years after HSCT, EBV negative |
| T-cell disease | ||||
| 10 | WF | 9 | 15 | Died, T-cell lymphoma |
| 15 | HM | 8 | Alive (15 y) | Alive 2 years after HSCT |
| 18 | AM | 4 | 9 | Died, 4 years after HSCT, T-cell lymphoma |
| NK-cell disease | ||||
| 19 | HM | 7 | Alive (14 y) | Alive 2 years after HSCT in complete remission |
A indicates Asian; B, black; BMT, bone marrow transplant; CTLs, cytotoxic T lymphocytes; F, female; H, Hispanic; HSCT, hematopoietic stem cell transplant; LCL, lymphoblastoid cell line (EBV-transformed B-cell line); LMP, latent membrane protein; LPD, lymphoproliferative disease; M, male; MDS, myelodysplastic syndrome; and W, white.